信达生物(01801.HK)扩大与礼来创新生物药授权许可
信达生物(01801.HK)公布,与礼来制药达成方共同在中国开发的抗PD-1单克隆抗体免疫肿瘤药物达伯舒的扩大授权许可协议。据此,礼来将获得达伯舒在中国以外区域的独家许可,并计划推向美国和其他地区市场。公司将收到2亿美元首付款,并有资格获得高达8.25亿美元潜在开发和商业化里程碑付款,以及双位数比例的净销售额提成。
达伯舒是公司和礼来在中国共同合作研发的具有国际品质的创新生物药。国家药品监督管理局已批准其用於治疗至少经过二线系统化疗的复发/难治性经典型霍奇金淋巴瘤,并入选2019版中国临床肿瘤学会淋巴瘤诊疗指南。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.